throbber
2005
`
`The Official Compendia of Standards
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 1
`
`

`

`2005
`
`USP 28
`
`NF 23
`
`THE UNITED STATES PHAR1\1ACOPEIA
`
`THE NATIONAL FORMULARY
`
`By a11tltority qf the United States Pharmacopeial
`Co11ve11tion, Inc., meeting at JVashi11gto11, D.C,
`April 12- 16, 2000. Prepared by the Council of Experts
`and published by the Board qf Trustees
`
`Official fiwn Ja1111a,y / , 2005
`
`The designation on the cover of this publication, "USP NF.
`2005," is for case of identification only. The publication
`contains two separate compendia: The V11itcd States
`Plwrmacopeia, Twenty-Eighth Revision, and the National
`Formulary, Twenty-Third Edition.
`
`UNITED STATES PHARMACOPEIAL CONVENTION, INC.
`12601 Twinbrook Parkway, Rockville, MD 20852
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 2
`
`

`

`NOTICE AND WARNING
`
`Co11ccmi11g US. Patl!Tlt or Trademark Rights
`
`The inclusion in the U11i1ed States Pltan11acopl!ia or in the Natio11a/ FormrtlmJ' of a monograph on any drug
`in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of,
`or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and
`privileges nrc vested in the patent or trademark owner, and no other person may exercise the same without
`express permission, authority, or license secured from such patent or trademark owner.
`
`Co11ccmi11g Use of USP or NF Text
`
`Use or the USP- NF is subject to the terms and conditions or the USP- NF License Agreement. Attention
`is called to the fnct that USP and NF text is fully copyrighted. Authors and others wishing to use portions
`of the text should request permission to do so from the Secretary of the USPC Board of Trustees.
`
`Copyright fi 2004 The United States Phannacopeial Convention, Inc.
`12601 Twinbrook Parkway, Rockville, MD 20852
`All righlr reserved.
`ISSN 0195-7996
`ISBN 1-889788-25-2
`Printed in Canada by Webcom Limited, Toronto, Ontario
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 3
`
`

`

`USP28
`
`Contents
`
`iii
`
`Contents
`
`USP 28
`
`Mission Statement and Preface . . . . . .
`
`v
`
`Admissions .. .. ... . . .. . ... ... .. ... .... . xxxm
`
`People . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xm
`
`Officers (2000-2005) . • . .. . . . .. . . . . ...... . . ...
`
`Board of Trustees (2000--2005)
`
`Council of Experts 2000-2005
`
`Council of Experts Executive Committee . .. • . • . . . ..
`
`Complex Actives Division
`
`. . . . . . . . . • . . • . . • . . . . .
`
`Executive Committee ..•.. . .•.. ..... . .• .• . •.. .
`
`Expert Committees . . . . . . .. .. . . .. .. ...• . . . . . . .
`
`Genera.I f<?licies and Requirements
`D1v1s1on . . . . . . . . . . . • . . . . . . . • . . . . . . . . . . .
`
`Executive Committee . . ... . .• . .... ... .. . . ... . .
`
`Expert Committees . . . .... . . . . ......• . •. • .... .
`
`Information Division
`
`Executive Committee
`
`Expert Committees . . . . . . . . . . . • • . . . . . . . • . • . • • .
`
`xiii
`
`xiii
`
`xiii
`
`xiv
`
`xiv
`
`xiv
`
`xiv
`
`xiv
`
`xiv
`
`xiv
`
`xv
`
`xv
`
`xv
`
`Noncomplex Actives and Excipients
`Division • • . . . . . . . . . • . . . • . . . . . . . . . . • • . . .
`
`xvii
`
`Executive Committee . . . . . . . . . . . . . . . . • . • . . . . . .
`
`xvii
`
`Expert Committees . . . . . . . . . . . . . . . . . . . • . . . . . . .
`
`xvii
`
`USP Reference Standards Committee
`
`USP- FDA Antibiotic Monograph
`Subcommittee . . . . . • . . . . . . . . . . • . . . . . . . . . .
`
`xviii
`
`xviii
`
`Headquancrs Staff . . . . . . . . . . . . . . . . . . . . . . . . . . .
`
`x, iii
`
`Collabora1ors During 2000 200-1
`
`. . . . . . . . . . . . . . . .
`
`. ·xi
`
`Members of the United S1ates Phannacopei31 Convention
`as of Jun<! 30, 2004 . . . . . . . . . . . . . . . . . . . . . . .
`
`xxvi
`
`Articles Admitted to USP 28 by Supplement . . . . . . . . xxxiii
`
`Change in Official Titles . . . . . . . . . • . • . . . . . . .. . . .
`
`xx.iii
`
`Revisions Appearing in USP 28 That were Not Included in
`USP 27 Including Supplements . . . • . . . . . • . • . .
`
`xxiv
`
`Articles Included in USP 27 but Not Included in USP 28 XXXV
`
`Commentary .. . .... . .... . ... . .. . .. . .. . xxxvi
`
`Notices
`General Notices nnd Requirements
`
`Monographs
`General Official Monographs for USP 28
`
`13
`
`Dietary Supplements
`Official Monographs
`. . . . . . . . • . . . . . . • . . . . . . . . . 2059
`
`General Chapters
`See page 2198/or detailed co11te11ts
`General Tests and Assays . . . . . . . • . . . . . . . . . . . . . . 2201
`
`General Requirements for Tests and Assays ... ... . . . 2201
`
`Apparatus for TcsL~ and Assays . . . . . . . . . . . . . . . . . . 2234
`
`Microbiological Tests . . . . . . . . . . . . . . . . . . . . . . . . . 2242
`
`Biological Tests and Ass:iys . . . . . . . . . . . . . . . . . . . . 2256
`
`Chemical Tests and Assays . . . . . . . . . . . . . . . . . . . . . 2292
`
`Physical Tests and Dct<!nninations
`
`. . . . . . . . . . . . . . . 2359
`
`-
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 4
`
`

`

`iv
`
`Co11te11rs
`
`General Infonnation
`
`Dietary Supplement
`
`2516
`
`2768
`
`Reagents, Indicators, and Solutions
`Reagents
`. . • . . . . . . . . . . . . . • . . . . . . . . . . . • • . . .
`
`2791
`
`Indicators and lndica1or Tcs1 Paper;
`
`. . . . . . . . • • . . . . 2852
`
`Solutions . . . . • • . .
`
`. . . . . • . . • . . . . . . . . . . . . . .
`
`2854
`
`Buffer Solutions . . . . . . . . • . . . . . . . . . . . . . . . • . . 2854
`
`Colorimetric Solutions
`
`. . . . . . . . • . . . . . . . . • • . . . 2854
`
`Test Solutions
`
`. . . . . . . . . . . . . . . . . . . . . . . . . • . . 2855
`
`Volumetric Solutions
`
`. . . . . . . . . . . . . . . . . . . . • . . 2862
`
`Reference Tables
`Conllliners for Dispensing Ca11sules and Tablets . . . .. . 2869
`
`Description and Relative Solubility of USP and NF
`Articles
`. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2875
`
`Approximate Solubilities of USP and NF Articles
`
`. . . . 2919
`
`Atomic Weights . . . . . . . . • • . . . . . . . . . . . . . . . . . . . 2927
`
`Alcoholometric Table . . . . . . . . . . . • . . . . . . . . . • . . . 2930
`
`Intrinsic Viscosity Table . . . . . . . . . . . . . . . . . . . . . . . 2932
`
`Thcnnometric Equivalents
`
`2934
`
`NF 23
`
`People
`Sl!e USP 28
`
`viii
`
`Admissions
`Articles Admiltcd to NF 23 by S11pplt!m1!11I • . . • • • . . . 2940
`
`Revisions Appearing in NF 23 that were not Included in NF
`22 Including S11pp/c111e111.r • • • • • • • . • • . . • • • • • . 2940
`
`USP 28
`
`Excipients
`USP and NF Excipicnts, Listed by
`Category
`. . . . . . . .
`. ... . ....•... .. . . .
`
`Notices
`General Notices and Requirements
`
`. . • . . . . . . . . . . . .
`
`:?9-45
`
`Monographs
`Official Monographs for NF 23 . . . . . . . . . . . . . . . . . . 2947
`
`General Chapters
`See pagl! 2198 for detailed ,·0111c111.r
`General Tests and Assays See USP 28, page 2201
`General Information Sec USP 28, page 2516
`
`Reagents
`Reagents Sec USP 28, page 2791
`Indicators and Indicator Test Papers See USP 28, page
`2852
`Solutions &•c USP 28, page 2854
`
`Reference Tables
`See USP 28, page 2869
`
`Appendices
`Articles of Incorporation ..... . ........... ..• . , .
`
`31 I I
`
`Constitution and Bylaws . . . . . . . . . . . . . . . . . . . . . . . 3112
`
`Rules and Procedures .... .... . • .... . ....... . . . 3123
`
`USP Communications Policy
`
`. . . . . . . . . . . . . . . . . . . 3128
`
`USP Document Disclosure Policy . . . . . . . . . . . . . . . . 3129
`
`Proceedings • . . . . . . . . . . . • . . . . • . . . . . . . . . . . . . . 3131
`
`Index
`Combined Index to USP 28 and NF 23 . .... .. ·;·· ·. 3135
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 5
`
`

`

`non (!eteetor and contains a suitable column, 1.8 m x 2.0 mm,
`cd with 5% liquid phase G2 on support SIA. The column and
`lion port are maintained isothennally at 170° and 180•,
`·vely. Using a suitable carrier gas, adjust the flow rate so
`the derivatized pantolactone elutes in al!out 4 minutes.
`ograJ>!l five injections of the Standard solution 2, and
`the peak responses as directed under Procedure: the relative
`deviation of the peak response ratios (Rs) of the five
`·ons is not more than 2.0%. The retention time of the derivatized
`Jactone is about 0'.75 relative to that ofilie derivatized internal
`In a suitable chromatogram, the resolution factor between
`ewo peaks is not less than 2.0.
`ure--lnject about 0.5 µL of Standard solution 2 into the gas
`tograph, record the chromatogram to obtain not less than 40%
`maximum recorder response, and measure the peak responses of
`derivatized pantolactone and the derivatized internal standard.
`·1ar1y inject about 0.5 µL of the Test solution, record the
`o'gram, and measure the peak responses of the corresponding
`ents. Calculate the quantity, in mg, of pantolactone in the
`n of Preparation taken by the fonnula:
`0.4CI..RulRs),
`· h Cs is the concentration, in mg per mL, of USP Pantolactone
`in Standard solution I, and Ru and Rs are the ratios of the peak
`due to the pantolactone to that due to the internal standard
`from the Test solution and the Standard solution 2,
`·vely.
`requirements-It meets the requirements for Refractive
`, Water; Residue on ignition, Limit of aminopropanol, and Assay
`Dexpanthenol.
`
`Dextran 1 is a low molecular weight fraction of
`tran, consisting of a mixture of isomaltooligosac(cid:173)
`·des. It is obtained by controlled hydrolysis and
`·onation of dextrans produced by fermentation of
`conostoc mesenteroides (strain NRRL B-512; CIP
`S9, or its sub-strains, for example L. mesenteroides B-
`2F; NCTC, 10817), in the presence of sucrose. It is a
`se polymer in which the linkages between glucose
`'ts are almost exclusively a.-1,6. Its' weight-average
`;IIOlecular weight is about 1000.
`:facu2ing and storage-Store in well-closed containers at a
`~ r e between 4° and 30°.
`LllleUag-Wherc it is int~ded for use in preparing injectable
`: : : forms, the label states that it is sterile or must be subjected to
`processing during the preparation of injectable dosage forms.
`~! Reference standards {I J}-USP Dextran I RS. USP
`-0/oxinRS.
`Wntlllcation-
`~ Infrared Absorption ( I 97K}-To I to 2 mg each of USP
`-..iran 1 RS and the sample add one to two drops of water, grind in
`;.;:ie mortar for I to 2 minutes, add about 30Q mg of potassium
`de, and mix to a slurry. [NOT&-Do not grind.} Dry under
`~ at 40" for 15 minutes, and if it is not dry, continue drying for
`==.,~_! 5 i_ninutes. Crush the residue, prepare a disk, and run the IR
`-.-uwn with a blank potassium bromide disk in the reference beam.
`~ I~ meets the requirements of the test for Molecular weight
`--ibution•and average molecular weight.
`~rb~nce {851}-The absorbance of a 15% solution in water at
`nm 1s not more than 0.12, water being used as the blank.
`~ c ~tadon (78IS}: between +148° and +164° at 20•, for a
`~ 10 water, on the dried basis (dry at 70° under vacuum to
`"!'IIIUlllt weight), and corrected for the content of sodium chloride.
`~blal llmlts (61)-The total aerobic microbial count does not
`I01 cfu per g, detennined by plate-count; and the total
`b"
`ltled molds and yeasts count does not exceed IO cfu per g.
`
`Official Monographs I Dextran
`
`601
`
`I
`
`Bacterial eodotoxios (85) (where it is labeled as intended for use in
`not more than 25.0 USP Endotoxin
`the preparation of injcctables):
`Units per g.
`pH {791 }: between 4.5 and 7.0, in a 15% solution in water,
`Loss on drying {731 }-Dry it at I 00" to I 05° for 5 hours: it loses not
`more than 5.0% of its weight.
`Heavy metals, Method II (231 ): not more than 5 µg per g.
`Limit of alcohol and related impurities--
`Test solution- Proceed as directed for Test solution in the test for
`Limit of alcohol and related impurities under Dextran 40, except to
`use S.Og ofDextran I.
`Standard solution, Chromatographic system, and Procedure-(cid:173)
`Proceed as directed in the test for Limit of alcohol and related
`impurities under Dextran 40, The total area of peaks from impurities
`in the Test solution docs not exceed the area of the n-propyl alcohol
`solution peak.
`Limit of sodium chloride-Dissolve 5 g of Dextran I, accurately
`weighed, in I 00 mL of water. Add 0.2 ml of potassium chromate TS,
`and titrate with 0.1 N silver nitrate VS (see Titrimetry (541 ) ). Each
`mL of 0.1 N silver nitrate is equivalent to S.844 mg of sodium
`chloride: not more than 1.5% of sodium chloride is found.
`Limit of nitrogenous Impurities (461 ) (where it is labeled as
`intended for use in the preparation of injectables)-
`Sulfate solution- To I 000 ml sulfuric acid add 5 g of anhydrous
`cupric sulfate and 500 g of potassium sulfate. Dissolve by heating,
`and store at 60°. [NOTE-If storage at 60'· is not possible, prepare a
`smaller quantity of Sulfate solution on the day of use, adjusting
`proportions accordingly.]
`/ndicatc>r-,-Dilute a mixture of 20 mL of, a 0.1 % solution of
`bromocresol green in alcohol l!Jld 4 mL of methyl red TS with water
`to 100 mL.
`Procedure-Transfer 0.2g Dextran I, accurately weighed, to a
`micro-Kjeldahl flask, Add 4 mL of Sulfate solution. Heat until the
`solution exhibits a clear green color and the sides of the flask are free
`from carbonaceous material. Cool, cautiously add 30 mL of water,
`mix, and transfer the solution to a steam distillation unit. Rinse the
`Kjeldahl flask with three 5-mL portions of water, adding the washings
`to the solution. Add IS mL of 45% sodium hydroxide solution,
`immediately close the distillation apparatus, and start steam
`distillation immediately. Receive the distillate in I mL of Indicator
`and sufficient water to cover the end of the condensing tube. Upon
`completion of the distillation, remove the receiving flask, and rinse
`the end of the condensing tube with a small quantity of water, adding
`the rinse to the distillate. Titrate the distillate with O.OION
`hydrochloric acid until the color changes from blue to reddish
`violet. Perform a blank .detennination1 and make any necessary
`correction. The corrected volume of O.OION hydrochloric acid
`required to change the color does not exceed 0.1 S mL ( 110 ppm of
`nitrogen).
`Molecular weight distribution and average molecular weight(cid:173)
`Mobile phase-Prepare a filtered and degassed solution of sodium
`chloride containing 2.9 g per liter.
`Calibration sc>lution-Prepare a solution containing about 0.45 mg
`of isomaltotriose (3 glucose units) and 0.60 mg of sodium chloride
`I
`per mL.
`Reference solution-Prepare a solution of USP Dextran I RS in
`Mobile phase containing 6.0 to 6.5 mg per mL.
`Test solution-Prepare a solution of Dextran I in Mobile phase
`containing 6.0 to 6.5 mg per mL.
`· Chromatographic system (see Chromatography (621}}--The
`liquid chromatograph is equipped with a differential refractive
`index detector and two I 0-mm x 30-cm columns in series that
`contain packing L54 and are maintained at 20-25•. The flow rate is
`0.07 to 0.08 mL per minute, maintained constant to ± I¾.
`Procedure-Inject about 100 µL of the Ca/ibratic>n solution,
`record the chromatogram, and note the retention times of the peaks.
`Separately inject equal volumes (about 100 µL) of the Reference
`solution and Test solution, and record the chromatograms. Using the
`retention times in the chromatogram of Calibration solution, identify
`the peaks due to isomaltotriose and sodium chloride in the
`chromatograms of Reference sc>lutic>n and Test sc>lution. Disregard
`the peak due to sodium chloride in Reference solution and Test
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 6
`
`

`

`602
`
`Dextran
`
`OJJ1cial Monogmpl,s
`
`USP 28
`
`so/11ticm. Calculate the weight-a\cragc mokcular weight, M-,. by the
`fonnula:
`
`kll ;M.,
`in whid 1 11: is the weight )'lmponion of oligosaccharidc i. and .\/, is
`the molecular weight of ohgosacclmride i. Use the following
`molec.'lllar \ I eight values for calcul,llion:
`11!0
`Glucose
`342
`lsomaltosc
`504
`lsomahotriose
`666
`lsomaltotctraose
`828
`lsomaltopcntaosc
`990
`lsomultohcxaosc
`1152
`lsomahohcptaosl!
`1314
`I somaltooctaosc
`1476
`lsomaltononaose
`1638
`lsomaltodL'Caosc
`1800
`lsomalloundecaosc
`1962
`lsomaltododecaose
`2124
`lsomaltotridecaosc
`2286
`lsomallotetradccaose
`2-148
`lsomollopentadecaose
`2610
`lsomaltohexadecaosc
`2772
`lsomaltohcptadccaose
`2934
`lsomaltooctadecaose
`3096
`lsomaltononadccaose
`Calculate the amounts of the fractions with fewer tl1un 3 and with
`more than 9 glucose units for the Refen:11u solutio11 and the Test
`.wl11ticm: the M. and amounts of the fractions obtained for the
`Refere11ce .m/11Jio11 are within the values stated in the data sheet that
`ac,;ompanies USP Dextran I RS. TheM •. ofDextran I is between 850
`and 11 SO. The fraction with fewer than 3 units of glucose is less than
`15%, and the fraction with more than 9 units of glucose is less than
`20%.
`
`Dextran 40
`
`Dcxtrans.
`Dextrans
`
`(900-1-54-0].
`
`» Dextran 40 is derived by controtle~ hydrolysis and
`fractionation of polysaccharides elaborated by the
`fermentative action of certain strains of le11co11ostoc
`mese11teroides {NRRL, 8.512 F; NCTC, l 0817) on a
`sucrose substrate. It is a glucose polymer in which the
`linkages between glucose units are almost entirely of the
`cc-l: 6 type. Its weight average molecular weight is in the
`35,000 to 45,000 range.
`Packaging and storage-Preserve in well-closed containers. Store at
`25' , excursions permitted between 15 and 30' .
`-
`Labeling-Where it is intended for use in preparing injectable
`dosage forms, the label states that it is sterile or must be subjected to
`furtller processing during the preparation of injectable dosage fonns.
`USP Rdercnce standards { 11 }-USP Dextran 40 RS. USP De.ttrat1
`4 Calihratio11 RS. USP Dettrat1 JO Ca/ibratio11 RS. USP Dcxtra11 40
`Calibration RS. USP De."Ctrall 70 Calibratio11 RS. USP De.'Clra11 150
`Calibratio11 RS. USP De:r:tra11 V. Marker RS. USP Dextra11 40 System
`Suitability RS. USP E11doto."Ci11 RS.
`Color or soludon-The nbsorb:mce ofa solulionin water (I in 10),
`measured in u 4-cm cell detennined nt 375 nm against a water blank,
`is not greater than 0.20.
`ldcntlficallo-
`!,!{rared Absorption ( 197K).
`A:
`B: Prepare four Test solutions of Dextrun 40 in water, in such a
`manner that the concentrutions ore accurately known and npproxi(cid:173)
`motely evenly distributed in the range or 2% to 0.5%. Using a
`cupillo.ry tube viscosimeter having dimensions such that the flow time
`or water is not less ~an 100 seconds, measure the flow times ofwnter
`
`iscosity numbci;
`
`and or the Test so/11tio11 at 20 . Calculate thi:
`c-Jch of the Test solutil/11.1· by the fonnula:
`lln[(R11 )(l • t )]) I C.
`in which R, is the rntio of the densny of the individual Test ml11ti,111 1c •
`that of\\ater; rand I arc the fiO\\ tunt:, for tht! r.m solutimr and water
`respectively; and C is the concentration, in g per ml , ofDcxtran 40 j~
`r~ of each of the IL"
`the T.:H so/111io11. PlOI th<.? ,·i,cosit} num
`.m/11tim1s against their rc~pcUi\ <.? concentrations, and clra1\
`rhc
`straight line of best fit through the points and extrapolat<.? tn 2c
`concentration: tho: rnlue of the nitcr.:cpt is bct11ccn 18 and :n mlr,cr
`g.
`SpeciHc rotation (78 IS 1:
`bt!l11 ct:n T 195 and .,.. 203 .
`T1:w .w/11tit111: 20 mg per ml, hcJh:d, if necessary, on a watcrb.uJi
`to dissolve.
`Bactcriul cndotoxins (851 /11-/wc 11 is lc1hel1!tl us i11te11cl.·dJ11rrL1"e ui
`the prc:parcuim1 of i11jc:c 111/Jh•~)- \Vhcn tested in Sodium Chloride
`Injection { I in I 0), it contains not more than 1.0 USP Endotoxin Unit 1
`per ml.
`Inject intravenously 1.0 ml of a sterile I in 10 solution or1
`Surety-
`10% Dcxtran 40 in saline TS into each oflive mice weighing 18 ~ !
`20 g. The injection period is not less than IO seconds and not greaia
`than 15 seconds, If there arc no deaths within 72 hours, it meet~ the
`requirements of the test. If I or more animals die, continue the !Cit
`using 10 mice weighing 20 ± 0.5 g. If all animals sur\'ive for 7l
`hours, the requirements of the test arc met.

`pH (791}: between 4.5 and 7.0, in a solu1ion (! in 10).
`Loss on drying (731 )-Dry it at l05 for 5 hours: it loses not
`than 7.0% of its weight.
`Sulfute (211 )-A 1.5-g ponion shows no more sulfate
`corresponds to 0.45 mL of 0.020 N sulfuric acid (0.03%).
`Hcuvy metals, Met/rod fl (231 ): 5 11g per g.
`Limit or nitrogenous Impurities (ll'hc:re it i1· lubell!d as i11te11dec/
`•
`use i11 tire pn:puratio11 of i11jcctab/c•s)-
`f.
`S11{futc: .m/11tio11- To IOOO ml of sulfuric acid add 5 g ofanhy
`cupric sulfate and 500 g of potassium sulfate. Dissolve by hea ·
`and store at 60 • [NOTE- If storage at 60 is not possible, pre
`.
`smaller quantity of S11lji11e sol111io11 on the dny of use, adjusting1
`proportions accordingly.]
`.,.
`h1dicu1<1r Dilute 11 mixture of 20 ml of a 0.1% solutio11l
`bromoci:c5ol green in o\coliol and 4 mL of methyl red TS will] '
`to 100 ml.
`Procedure Transfer 0.2 g, accurately weighed, to a m!
`Kjcldahl flask. Add 4 mL of S11(fat1! solution. Heat until the sol
`c;xhibits n clear green color und the sides of t11e Ollffek nre free (cid:173)
`carbonaceous material. Cool, ond trJnsfer the solution to a s
`distillation unit. Rinse the Kjcldahl flask thn.-c times with 5 mt
`water, adding the washings to the solution. Add 15 mL of"4
`sodium hydroxide solution, immediately close .the distill ·
`apparatus, and commence steam distillation without delay. Rec ·
`the distillate in I mL of /mlit·ator in a I 00-mL tlask, keeping the
`of the condensing tube below the liquid surface for 5 minutes •
`above the liquid surface for I minute. Upon completion of ·
`distillation, remove the receiving flask. and rinse the end of
`condensing tube with a small quantity of water, addi~g the ri~c'!J
`distillate. Titrate the distillate with 0.0 ION hydrochlorii,: ac.id uµlll
`color changes from blue to reddish violet. Pcrfonn n b
`determination, and make any necessary correction.:. The co(cid:173)
`volume of 0.0 ION hydrochloric acid titrated docs not exceed .D.l
`ml (0.01 %, as N).
`.
`Limit of alcohol and related Impurities--
`Test so/111io11- Dissolve without heating 5.0 g in 100 m~ of..
`and distill the solution, collecting the first 45 mL or the d. ·"· ·
`Dill!te the distillate 1\ith water to 50.0 ml, and mix.
`Sta11clarcl so/mjo11- To 25.0 mL of the Test so/111io11 add~-~
`a 1.5% (wlv) solution of 11-propyl alcohol.
`Chromatographic system- The gas chroJ11atograP,h is c;g
`with II flame-ionization detector and contains a 2-mm x
`•
`column packed with . su[!port S3. The column tenipe '
`mnintaincd at about 160°, lhc injection porl temperature is mui' .
`at about 240 , and the detector is maintained at iibout 2 I 2J
`carrier gas is nitrogen, flowing [!t ·a rote of about 25 mL per
`[Nore;...fnjector seals may dcteri·orate nflcr multiple· injections
`Standard ond Test so/11tio11s. Inspect the seals before ·making a
`of injections.]
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 7
`
`

`

`Official Monographs I Dextran
`
`603
`
`give values or weight average molecular weight, M~ within 5% of the
`labeled values for each of the Calibrotio11 solutions and 180 ± 2 for
`dextrose. Chromatograph the System suitability sofutio11, and record
`the peak responses as directed for Procedure. Calculate 'Xiw of the
`total molecular weight distribution using the same method as directed
`for the Calibratio11 solutio/lS, but inserting the now known values of
`bi, b:, b,, b,, and bs. It is between 39,000 and 46,000.
`Similnrly, calculate M~ of the high-fraction dextr.ln eluted through
`section II by the formula:
`
`in which II is defined by the relations:
`
`L )', > 0.1 LY, .
`••I
`•
`(
`)
`I •
`i • 1
`
`I
`
`It is between 111,000 nnd 135,000.
`Similarly, calculate 'Xt of the low-frJction dcxtran eluted in nnd
`ofter section III by the formula:
`
`in which III is defined by:
`
`f _\', > 0.1( t .r,) .
`
`•
`
`I
`
`, • "' -
`
`I
`
`It is between 6000 and 9000.
`Pmccd11rr.• Chromatograph a 50-11L I olumc of lhe Test so/111icm,
`and record the pcak_!!!sponses. Calculate ,alttcs of the weight average
`molecular weight, ,If., of the Iota I molecular 1\eight distribution of
`the high-fr.iction dcxtran, and oftl11: 101\-fntcuon de~tran as directed
`for Srftcm S11itabili(1• under C/m,mawgraplzy (621) the values arc
`bcmccn 35,000 and 45,000, nol more than 120,000, nnd not less than
`5,000, rcspccth ely. With 1hc I alu.:s of /1 , b,. /,1 , b., and b,, obtained
`11 ith the Calilw11tio11 sol11tim1s under C/11nmmog[aphk J):W !III,
`calculate the number avcmge molecular weight, M., of the total
`molecular weight distribution of the Test solwio11 by substituting the
`
`F
`
`OMiJIIIIJ'l!'--1,,cparatcly inject equal volwnes (about l µL) of the
`·• n; the Standard sol11tio11, nnd n 0.05% (w/v) solution of n,
`.. bol and wnter, nnd mcnsure the peak R!Sponses. After
`,!for any impurities in the 11-propyl alcohol solution nnd
`·ta1 area of peaks from impurities in the Test so/111io11 does
`tlic area of the 11-propyl nlcohol solution peak.
`· · c'lmpurlties (ll'herc it is labeled.as i11tCt(ded for '!S! i11 tlzc
`II of injectables)- Prepnre n stenle solution contammg I 00
`iit. Sodium Chloride Injection. At intervals or about 48
`,
`· ~ect three 0.5-mL doses into the peritonenl cavities of each of
`-~igs. At 14 day~ ofter the first intr.1pcrito!1cal i~jection, inject
`'mll. intiavi:nously mto each of 3 of the guinea pigs, nnd at 21
`1Rl1 the other 3 b'llinea pigs similarly. Observe the nnimals for
`•
`after each intrJvcnous injection and ngain 24 hou~ later.
`exhibit no evidence of nnaphylactoid reactions, such as
`' g; bristling of hair, or respiratory distress.
`Jar w~lght distribution and weight and number nerage
`lir welghts-

`"1fohi/e j,has Prepare a suitable degnsscd and filtered solution
`tfifllllining 7.1 g of nnhydrous sodium sulfate per L in water.
`£4/ibrrztion sollltio11s- Separately dissolve USP Dextr.ln 4 Cali•
`·on RS, USP Dextran IO Calibration RS, USP Dcxtran 40
`·on RS, USP Dcxtran 70 Calibration RS, and USP Dc:xtran
`· €alibration RS in Mobile phase to obtnin solutions each
`· ing 20 mg per ml.
`'arker sol111io1 Prepare n solution in Mobile phase containing 3
`fdexttose and 3 mg of USP Dextran v. Mnrker RS per ml.
`suitability so/u1io11~ Prepare a solution of USP Dextr.ln 40
`Suitability RS in Mobile phase containing 20 mg per ml.
`solutio1 Prepare a solution of Dextr.ln 40 in Mobile p/zuse
`· ing 20 mg per ml.
`matograp/ric system (sec Cl1rvli1atograp/,y {621 ) )- The
`• chromatograph is equipped with o refractive index detector
`llliee 7.5-mm x 31km columns containing packing L38, and
`'ncd at n constant temperature. Chromatograph the Marker
`'011. and record the peak responses as directed for Procedure: the
`profile shows two peaks, the first due to the 1: marker, the
`-d'due to dextrose. Determine the void volume, V.,, or the system
`le inflection point or the ascending port of the first peak.
`· e the total volume, V,, of the system as the mwdmum or the
`· ,Peak; the tailing factor, t, of the dextrose pe.ik is not more than
`• 1111d the relative stnndnrd deviation or the ratio 1:1 v, is not more
`1%. Chromatograph eoch or the Calibration sol11tio11s
`ly, and record the peak responses as directed for Procedure.
`each profile into at least 60 vertical sections or equal volume
`ts. (The actual number o r sections is represented by the
`le a in the equations below.) Record y., the heig~t abOV\: the
`, com:sponding to each value or,,,, tlte vo Jume eluted at that
`.
`~on.For each value of,,,. calculate the distribution coefficient, K,,
`•1-the fonnula:
`
`(1', - V.,) /( l'r - V,).
`Fmd i!j>propriate values of b,. b,. b,, b., and b,, using a suitable
`. lllelhod, that, when substituted in the equation:
`
`~ the resulting , alucs of ,If, substitu1ed, along \\ i1h their
`iponiJing ,alucs ofy, in tht: equation:
`
`M.
`
`I
`
`_i l'. M,)/ i .\,,
`
`, • J
`
`I
`
`-~ Gauss-Newlon mc1hml. mo,hticJ by Hanley {sec 0 . llanlcy
`G.k:ii"'elrits. 3 (1961 )], and the G Nilsson and K. Nilsson method fscc
`. .!~_'•in and K. Nilsson ] C hmmat, 101, 137 (197-l))arc suitable methods.
`•
`' C-fl1ting pmgrJm cap~blc of nonlinear regression may be used.
`
`,L ofYiallf
`1c distillal'-
`dO;mL'-"
`
`PGR2020-00009
`Pharmacosmos A/S v. American Regent, Inc.
`Petitioner Ex. 1085 - Page 8
`
`

`

`604
`
`Dextran O//u ial Mo11ograph1·
`
`<.:orrcsponding \ alu,:.~ of .M , alony: with their corresponding values of
`_, • in the ~-quarion:
`
`The numhcr a\ er.ti!.: molecular \\cighl 17_, i, hct\\ ccn 16,000 :md
`30,000. \\11cn: Deman 40 i~ labeled as mrcndcd for use in the
`preparation of injccrahks, the rJtio M, I . is 111 1hc I .4 10 I 9 rJngc.
`
`Dextran 40 in Dextrose Injection
`
`» Dextmn 40 in Dextrose Injection is a sterile solution of
`Dextran 40 and Dextrose in Water for Injection. It
`contains in each I 00 ml not less than 9,0 g and not more
`than I I .0 g of Dextran 40 and not less than 4.1 g and not
`more than 5.0 g of dextrose (C6H1206)- lt contains no
`bnctcriostatic agents,
`
`Puckuging 11nd storage-Preserve in single-dose glass or plastic
`containers.
`Lubeling- The label states the total osmolnr concentration in
`mOsmol per liter. Where the contents arc less than I 00 mL, the
`label uhematively may state the total osmollll' concentration in
`mOsmol per mL.
`USP Reforence st11nd11rds ( 11 )-USP Dcxtro.w! RS. USP E11do1rui11
`RS-
`Color or solution-Its absorbancc, detennined at 375 nm against a
`water blonk, is not greater than 0.06.
`ldentilicathm-Dilutc a portion quantitatively with dextrose solu(cid:173)
`tion (4.5 in I 00) to n concentration of about IO mg of Dextran 40 per
`mL. Using a capillary tube viscosimctcr having dimensions such that
`the now time of water is not less than I 00 seconds, measure the flow
`times of the diluted Injection and that of a dextrose solution (4.5 in
`I 00) at 20=. Calculate the intrinsic viscosity by the formula:
`lln[(R11)(1/ 10)]J / C,
`in which R,, is the ratio of the density of the diluted Injection to that of
`the i.lextrosc solution; t ani.1 10 arc the flow times for the ililuted
`Injection and the dextrose solution, respectively; and C is the
`conccntmtion, in g per mL, of Dc1ctran 40 in the diluted Injection: the
`intrinsic viscosity is between 18 lltld 23 mL per g.
`Bacteriul cndotoxins (85)-11 contains not more than 1.0 USP
`Endotoxin Unit per mL.
`Sterility (71 )-It meeL,; the requircmcnL,; when tested as directed for
`Mcmbrmw Filtmrio11 under Te.rt for Sterility ,f the Pmd11ct to he
`fa:amil/l:d.
`pH (791): henvccn 3.0 ond 7.0.
`Hcin-y metals, Mer/wt/ II (231): 5 µg per mL.
`Limit of 5-hydroxymcthylfurfurnl nnd related substances(cid:173)
`Dilute an accurately measured volume of Injection, equivalent to
`1.0 g of C6H120• · H20, v..ith water 10 500.0 mL. Determine the
`absorbancc of this solution in 11 I-cm cell at 284 nm, using water as
`the blank: the nbsorbance is not more than 0.25.
`Otbt,?r requirements-It meets the requirements for /11.fecrions {I)
`and for Partie11larc Matter i11 bifccti011s (788).
`Assay for dextrose--
`Mobile p/iar,--Use filtered and degassed 0.01 N sulfuric acid.
`System .rnilahility prcparatio11- Preparc a solution in water
`containing 5 mg each or dextrose and xylitol per mL.
`Sta11danl prcparatio11- Dissolve no accurately weighed quantity of
`USP Dextrose RS in water to obtain a solution having o known
`concentration of about 5 mg of dextrose monohydratc per mL.
`
`.
`,11-.my preparation Transfer an accur.itely measured volume
`Injection, equivalent to about 250 mg of dextrose monohydr-Jlc, 101 •
`50-mL volumetric llask, dilute \\ith water to volume, and mix.
`Chromatographic system (sec Chromatograplir (621 ))-TII,
`liquid chromato1m.1ph is equipped with a rcfracthe index dct~
`and a 7.8-mm x -30-cm column cont:uning packing LI 7. ThccollllllQ
`und, 1f necessary, the detector arc maintained at u i:on51a111 ,
`temperature of about 40 , and !he flow rate 1, ahout O 6 ml 11'!
`minute. Chromatograph the 5_rtlc111 s11iwhili11 p rcparmim1, ar~
`measure the peak rc<;ponscs as direc_tcd for Pm ccd11n
`the rcsolut~
`R, between rhc dextrose and x:yhrol pcaJ.,., 1<; nm lc,s than 2 5
`Chromatogr,1ph the: Sta1Ult1nl pn·/1Cm1tio11 as dircct.::d for f'mcc,/11r, .
`the relative standard deviation for replicate in1cc11011, 1, not more tbai,
`1.5% for de:ittrose.
`Pmcc:drll'c - Inject c11ual volumes (about 50 11L) or the S11111dart
`pn'Paration and the .-lsm_r prq,aratimr into the chromarn~
`record the chromatograms, and measure the rc, ponsc, for lhc.
`dextrose peak

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket